Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 2,393–2,400 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Kezar Life Sciences Inc. Zetomipzomib (KZR-616-208) - (PORTOLA) Autoimmune Hepatitis (AIH) Phase 2a Hold Removed Subcutaneous Immunology
Kiniksa Pharmaceuticals International plc KPL-387 Recurrent pericarditis Phase 2/3 Ongoing Subcutaneous Cardiology
Kiniksa Pharmaceuticals International plc Mavrilimumab COVID-19-related acute respiratory distress syndrome (ARDS) Phase 2/3 Trial Discontinued Intravenous COVID-19
Kiniksa Pharmaceuticals International plc Abiprubart Sjogren's Disease Phase 2b Ongoing Intravenous Immunology
Kiniksa Pharmaceuticals International plc Vixarelimab (KPL-716) Prurigo nodularis Phase 2b Ongoing Subcutaneous #N/A
Kiniksa Pharmaceuticals International plc Mavrilimumab COVID-19 Phase 2 Trial Discontinued Intravenous COVID-19
Kiniksa Pharmaceuticals International plc Abiprubart (KPL-404) Rheumatoid arthritis Phase 2 Data Released Intravenous Immunology: Anti-TNF
Kiniksa Pharmaceuticals International plc Vixarelimab (KPL-716) Chronic Pruritus Phase 2 Trial Completed Subcutaneous N/A
1…298299300301302…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.